AbClon Inc

Chart & Performance

D1W1MN

P/E

—

P/S

76.53

EPS

—

Div Yield, %

—

Shrs. gr., 5y

5.83%

Rev. gr., 5y

11.21%

Revenues

4.71b

+101.47%

Net income

-17.91b

L+9.85%

CFO

-13.83b

L-3.93%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Founded in Seoul, South Korea, in 2010, AbClon Inc. is a biopharmaceutical company engaged in the discovery and development of antibody-based drugs, with operations spanning South Korea and Sweden. The firm's developmental pipeline encompasses therapies derived from distinct technological platforms: the NEST platform addresses breast and gastric cancers; the AffiMab platform targets colon cancer and various autoimmune conditions; and the CAR-T platform is engineered for hematologic and ovarian cancers.

URL

http://www.abclon.co.kr/

IPO date

Sep 18, 2017

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title KRW in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title KRW in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT